media – Page 54 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

More than 3,000 cases confirmed! No specific medicine! Are we ready for Chikungunya virus?

Recently, Diana Alvarez, head of the WHO’s arbovirus team, said that the transmission of Chikungunya virus has been found in 119 countries and regions, about 5.5 million people are at risk of this mosquito-borne virus, and a large-scale epidemic may occur. Confirmed cases have appeared in China. Since July, Guangdong has reported cases of Chikungunya virus infection. As of July 22, the number of infected cases has exceeded 3,000, and this number is still rising. Chikungunya virus, a once ignored “hidden threat”, is now spreading at an alarming rate in some parts of China, posing a challenge to public health security. Faced with this sudden outbreak, people can’t help but feel anxious and uneasy: What exactly is the Chikungunya virus? What is the progress of vaccines and special medicines? What is Chikungunya virus? The name of Chikungunya virus (CHIKV) comes from the Makonde language in Tanzania, Africa, which means “bent ...
- Source: drugdu
- 158
- July 25, 2025
Sanofi Acquires Vicebio for $1.15 Billion, Enhancing Respiratory Vaccine Pipeline

Sanofi announced an agreement to acquire biotech company Vicebio Ltd for $1.15 billion, expanding its respiratory vaccine pipeline and future capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ technology. According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront payment of $1.15 billion with milestone payments upwards of $450 million based on development and regulatory checkpoints. The deal is set to close in Q4 of 2025 and won’t drastically affect Sanofi’s Diving deeper Vicebio’s Molecular Clamp technology is one of the driving forces in the deal, as the technology enables researchers to stabilize naturally shaped viral proteins, enabling the immune system to recognize and react at an improved rate. This allows for accelerated development of liquid combination vaccines, which allows them to be stored in refrigerators. This eliminates the need for freezing and freeze-drying vaccines, making the production and distribution ...
- Source: drugdu
- 135
- July 25, 2025
COVID Boosters Protect People With Cancer

By Dennis Thompson HealthDay ReporterWEDNESDAY, July 23, 2025 (HealthDay News) — Cancer patients can be very vulnerable to a severe COVID infection, but COVID-19 vaccine boosters can be lifesavers for them, a new study says. COVID boosters reduced cancer patients’ hospitalizations and ICU stays by 29%, researchers report in JAMA Oncology. Overall, the vaccine boosters prevented one hospitalization or ICU admission for every 150 to 166 boosted patients, researchers found. “The reduction in hospitalizations was significant, and the number of patients we needed to treat to see a benefit to the boosters is quite low,” said senior researcher Jan Figueiredo, director of community health and population research at Cedars-Sinai Medical Center in Los Angeles. “This shows a great benefit to our cancer patients and should encourage patients to discuss vaccination with their healthcare providers,” she said in a news release. “Their immune systems can be weakened by their disease and ...
- Source: drugdu
- 143
- July 25, 2025
China’s innovative drug pipeline accounts for about 1/4 of the world’s total; Guangji Pharmaceutical fined 1.5 million yuan

National Medical Products Administration: Currently, China’s R&D pipeline for innovative drugs accounts for about 1/4 of the global total On July 23rd, according to statistics from the National Medical Products Administration, China approved 43 innovative drugs in the first half of the year, a year-on-year increase of 59%, approaching the annual number of approved innovative drugs of 48 in 2024. Yang Ting, Director of the Drug Registration Management Department of the National Medical Products Administration, stated that in terms of research and development pipelines, China currently accounts for about 1/4 of the world’s innovative drug research and development pipelines. In terms of clinical trials, we have about 3000 projects undergoing clinical trials every year, which ranks among the top in the world. It is reported that the National Medical Products Administration will focus on increasing policy supply, guiding and encouraging enterprises to carry out innovative drug research and development guided ...
- Source: drugdu
- 129
- July 25, 2025
【EXPERT Q&A】What contents need to be submitted for the registration application of domestic Class II medical devices?

Drugdu.com expert’s response: The registration of Class II medical devices in China requires submission of key documents covering risk analysis, technical specifications, testing reports, clinical evaluation, labeling, quality management systems, and authenticity declarations. Detailed requirements are outlined below: I. Foundational Qualification Documents Medical Device Registration Application Form: Must include core details such as product name, model/specification, structural composition, and intended use, signed and stamped by the legal representative or responsible person. Enterprise Qualification Proof: Copy of the business license (valid within its term). Medical Device Manufacturing License (if applicable; the registered product must fall within the approved scope). Personnel Qualification Proof: Identity, educational, or professional title certificates for the legal representative, enterprise leader, and quality manager (the latter must have a medical device-related background). II. Product Technical Documentation Product Technical Report: Covers design principles, structural composition, manufacturing materials, performance indicators, and production processes. Must provide the product technical requirement number and explain the basis for key ...
- Source: drugdu
- 115
- July 25, 2025
Targeting tumor cell stemness may hold the key to treating colon cancer more effectively

Colon cancer remains a major global health concern, ranking third among the most diagnosed cancers and leading causes of cancer-related death worldwide. One critical factor that makes treating colon cancer challenging is the presence of cancer stem cells. Though typically present in small populations, these powerful cells drive tumor growth, resist standard treatments, and often contribute to relapse. They achieve this through their “stemness,” a set of properties that enable these cells to self-renew and differentiate into other cell types. Thus, understanding how stemness might be controlled at the molecular level is essential for developing effective therapies for colon cancer. Over the past two decades, researchers have identified several key molecules involved in both the development of the colon and the progression of colon cancer. Among them are CDX1 and CDX2, two homeobox transcription factors that help establish and maintain the identity of intestinal epithelial cells. Another example is ...
- Source: drugdu
- 209
- July 24, 2025
Pharmapack

Organiser: Informa Exhibitions Group Time：January 21-22, 2026 address：1, place de la Porte de Versailles, 75015 Paris, France Exhibition hall：Paris Expo Porte de Versailles Product range: Design and innovation of drug delivery systems, as well as raw materials (aluminum, cardboard, plastics, and glass) Transformers, packaging machinery, production equipment, automation and assembly line systems, product and packaging design services, thermoformed packaging for parts and components Aerosols, ampoules, sprays, blisters, medical devices, pharmaceutical packaging, vials, unit doses Labeling and identification, medical pumps, medical bags, syringes, pen injectors, reconstitution systems, tubes, and more Pharmaceutical subcontractors, printing and labeling, instruction manuals, brochures, sterilization technologies and services, control, tracking, and anti-counterfeiting measures, transportation materials and services About Pharmapack： Pharmapack, the France Paris Pharmaceutical Packaging Exhibition, is France’s largest and most authoritative pharmaceutical packaging exhibition. It brings together leading global industry designers, pharmaceutical manufacturers, suppliers of pharmaceutical packaging and delivery systems, and attracts decision-makers from pharmaceutical companies, ...
- Source: drugdu
- 127
- July 24, 2025
GI Cancers On The Rise Among Younger Adults

By Dennis Thompson HealthDay ReporterMONDAY, July 21, 2025 (HealthDay News) — GI cancers among people 50 and younger are rising at an alarming rate, increasing in the U.S. faster than any other type of early onset cancer, according to a pair of new studies. Cancers of the colon, stomach and esophagus have all increased in recent years, threatening the health of younger Americans, researchers say. Between 2010 and 2019, cases of young-onset GI cancers rose by nearly 15%, researchers reported in the British Journal of Surgery. “Colorectal cancer is the most common early onset GI cancer worldwide, accounting for more than half of the cases, but it is not the only GI cancer that is rising in younger adults,” said senior researcher Dr. Kimmie Ng, director of the Young-Onset Colorectal Cancer Center at the Dana-Farber Cancer Institute in Boston. “Unfortunately, pancreatic, gastric, and esophageal cancers are also increasing in young ...
- Source: drugdu
- 431
- July 23, 2025
FDA Elevates Dubai Chocolate Spread Recall to Class 1 Over Salmonella Risk

By Denise Mann HealthDay ReporterMONDAY, July 21, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has escalated the recall of a popular Dubai chocolate spread sold nationwide to its highest alert level due to salmonella risks. So far, four cases of salmonella and one hospitalization have been linked to the outbreak, according to the CDC. World Market initiated the voluntary recall of a batch of Emek Gıda’s pistachio-cocoa spread on July 14, after samples tested positive for salmonella contamination. Three days later, the recall was updated to a Class 1 alert. The Class 1 designation signifies a “reasonable probability” that consuming the spread could cause serious illness or death, according to the FDA. Salmonella can cause serious and potentially fatal infections in young children, the frail or elderly, and others with weakened immune systems, the FDA warned. Symptoms of Salmonella infection in healthy individuals may include fever, ...
- Source: drugdu
- 184
- July 23, 2025
WuXi Biologics’ Five Manufacturing Sites Pass U.S. FDA Pre-approval Inspections; First Commercial Prefilled Syringe Filling Plant Approved

On July 21, WuXi Biologics announced that its five manufacturing sites successfully passed the U.S. Food and Drug Administration (FDA) pre-approval inspection (PLI) with zero critical findings and zero data integrity issues. The nine-day FDA inspection covered WuXi Biologics ‘ quality management system and the entire production process of its two bulk drug manufacturing plants (MFG1 and MFG5) and three drug product manufacturing plants (DP1, DP2, and DP5) in Wuxi, China. As the company’s first commercial prefilled syringe (PFS) filling plant, DP5 passed the regulatory inspection for the first time, laying a solid foundation for it to provide high-quality prefilled syringe production solutions to global customers. https://finance.eastmoney.com/a/202507213462123078.html
- Source: drugdu
- 180
- July 23, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.